Serum MicroRNAs as Predictors for HCV Progression and Response to Treatment in Pakistani Patients
- PMID: 36833368
- PMCID: PMC9957303
- DOI: 10.3390/genes14020441
Serum MicroRNAs as Predictors for HCV Progression and Response to Treatment in Pakistani Patients
Abstract
Hepatitis is one of the common liver diseases, imposing a heavy health burden worldwide. Acute hepatitis may develop into chronic hepatitis, progressing to cirrhosis and hepatocellular carcinoma. In the present study, the expression of miRNAs was quantified by real-time PCR, such as miRNA-182, 122, 21, 150, 199, and 222. Along with the control group, HCV was divided into chronic, cirrhosis, and HCC groups. The treated group was also included after the successful treatment of HCV. Biochemical parameters, such as ALT, AST, ALP, bilirubin, viral load, and AFP (HCC), were also evaluated in all of the study groups. We compared the control and diseased groups; these parameters showed significant results (p = 0.000). The viral load was high in HCV but was not detected after treatment. miRNA-182 and miRNA-21 were overexpressed with disease progression, while the expression of miRNA-122 and miRNA-199 was increased compared with the control, but decreased in the cirrhosis stage compared with chronic and HCC. The expression of miRNA-150 was increased in all of the diseased groups compared with the control, but decreased compared with the chronic group. We compared the chronic and treated groups and then all of these miRNAs were down-regulated after treatment. These microRNAs could be used as potential biomarkers for diagnosing different stages of HCV.
Keywords: HCC; biomarker; chronic; cirrhosis; hepatitis C; treatment.
Conflict of interest statement
The authors declare no conflict of interest relevant to this study.
Figures





Similar articles
-
Serum miRNA-27a and miRNA-18b as potential predictive biomarkers of hepatitis C virus-associated hepatocellular carcinoma.Mol Cell Biochem. 2018 Oct;447(1-2):125-136. doi: 10.1007/s11010-018-3298-8. Epub 2018 Feb 17. Mol Cell Biochem. 2018. PMID: 29455432 Clinical Trial.
-
The interaction between microRNA-152 and DNA methyltransferase-1 as an epigenetic prognostic biomarker in HCV-induced liver cirrhosis and HCC patients.Cancer Gene Ther. 2020 Jun;27(6):486-497. doi: 10.1038/s41417-019-0123-9. Epub 2019 Jul 18. Cancer Gene Ther. 2020. Retraction in: Cancer Gene Ther. 2022 Aug;29(8-9):1303. doi: 10.1038/s41417-022-00496-9. PMID: 31316135 Retracted.
-
Serum microRNAs; miR-30c-5p, miR-223-3p, miR-302c-3p and miR-17-5p could be used as novel non-invasive biomarkers for HCV-positive cirrhosis and hepatocellular carcinoma.Mol Biol Rep. 2015 Mar;42(3):713-20. doi: 10.1007/s11033-014-3819-9. Epub 2014 Nov 13. Mol Biol Rep. 2015. PMID: 25391771
-
Molecular Mechanisms Driving Progression of Liver Cirrhosis towards Hepatocellular Carcinoma in Chronic Hepatitis B and C Infections: A Review.Int J Mol Sci. 2019 Mar 18;20(6):1358. doi: 10.3390/ijms20061358. Int J Mol Sci. 2019. PMID: 30889843 Free PMC article. Review.
-
Hepatitis C virus in chronic liver disease and hepatocellular carcinoma in Taiwan.Princess Takamatsu Symp. 1995;25:27-32. Princess Takamatsu Symp. 1995. PMID: 8875606 Review.
Cited by
-
The Malignant Transformation of Viral Hepatitis to Hepatocellular Carcinoma: Mechanisms and Interventions.MedComm (2020). 2025 Mar 8;6(3):e70121. doi: 10.1002/mco2.70121. eCollection 2025 Mar. MedComm (2020). 2025. PMID: 40060195 Free PMC article. Review.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical